Skip Navigation

Advertise|Press|Contact|FAQ|About Us

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Family Medicine
Disease Category: Breast Cancer
Location: United States, WV

Clinical Trial Details

Overview

Research Study Summary

NSABP-B47 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

Purpose

This trial will determine whether the addition of trastuzumab to standard chemotherapy regimens improves invasive disease-free survival relative to chemotherapy alone.

West Virginia University - Clinical Trials Research Unit
1637 Health Sciences South, PO Box 9260
Morgantown, WV 26506
Phone: 304-293-7374

To Learn more
Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Facility Type

N/A

Contact

West Virginia University - Clinical Trials Research Unit
1637 Health Sciences South, PO Box 9260
Morgantown, WV 26506
Phone: 304-293-7374

View Map

CW ID: 176123

Date Last Changed: December 2, 2011


DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.